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Abstract
The relationship between diabetes and periodontal disease is bidirectional, but information
about the effect of chronic periodontitis on the levels of the glucoregulatory biomarkers lo-
cally in gingival crevicular fluid (GCF) is limited. The aim of this study was to compare the
levels of 10 glucoregulatory biomarkers in GCF, firstly in subjects with type 2 diabetes
(T2DM) presenting with and without chronic periodontitis and secondly, in subjects without
diabetes, with and without chronic periodontitis. The material comprised a total of 152 sub-
jects, stratified as: 54 with T2DM and chronic periodontitis (G1), 24 with T2DM (G2), 30 with
chronic periodontitis (G3) and 44 without T2DM or periodontitis (G4). The levels of the bio-
markers were measured using multiplex biometric immunoassays. Periodontal pocket
depths were recorded in mm. Subsets G1 and G2 and subsets G3 and G4 were compared
independently. Among T2DM subjects, GIP, GLP-1 and glucagon were significantly up-
regulated in G1 compared to G2. Moreover, there were no statistical differences between
the two groups regarding C-peptide, insulin, ghrelin, leptin and PAI-1. Comparisons among
individuals without T2DM revealed significantly lower amounts of C-peptide and ghrelin in
G3 than in G4. The number of sites with pocket depth 4mm correlated negatively with C-
peptide (Spearman’s correlation co-efficient: -0.240, P < 0.01) and positively with GIP and
visfatin (Spearman’s correlation co-efficient: 0.255 and 0.241, respectively, P < 0.01). The
results demonstrate that chronic periodontitis adversely influences the GCF levels of glucor-
egulatory biomarkers, as it is associated with disturbed levels of biomarkers related to the
onset of T2DM and its medical complications.
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Introduction
Diabetes mellitus represents a heterogeneous group of metabolic disorders associated with dis-
turbances of carbohydrate, fat and protein metabolism. There are two major classes of the dis-
ease: Type 1 and Type 2. Type 2 diabetes (T2DM) is characterized by elevated blood glucose
levels caused by increased production of glucose in the liver and increased peripheral insulin
resistance, which might eventually lead to a reduction in insulin secretion [1]. In sub-Saharan
Africa, T2DM is becoming increasingly prevalent, presenting a major public health burden in
countries with scarce resources [2]. In The Sudan, the prevalence is increasing to epidemic pro-
portions, affecting about 18 percent of the population [3]. Of particular concern is the fact that
the onset is insidious and the condition may remain undiagnosed for a long time. In this con-
text, the dental profession has a potentially important role and the condition may first be iden-
tified during a dental examination [4].
Periodontal disease is one of the most common diseases affecting humans [5]. Chronic peri-
odontitis is an inflammatory condition characterized by apical migration of junctional epitheli-
um, leading to formation of deep periodontal pockets around the teeth due to destruction of
periodontal tissue fibers and the supporting bone [6]. Periodontal pockets may host highly vir-
ulent microorganisms and if left untreated; the host inflammatory-immune response pro-
gresses leading to tissue destruction [7]. For many years, chronic periodontitis was regarded as
a local inflammatory condition, but recent research confirms that the condition has a systemic
impact as the total surface area of the ulcerated periodontal pockets may be in the range of 8 to
20 cm2, approximately the size of the palm of an adult hand [8]. Recently, more attention is di-
rected towards the systemic effect of chronic periodontitis including its role in the aetiology of
T2DM as well as its impact on the metabolic control and medical complications associated
with patients baring the disease.
The scientific literature however, shows lack of consensus about the risk of onset of T2DM
in subjects with chronic periodontitis. A review by Sima et al., [9] cited two longitudinal stud-
ies. The first study reported an odds ratio between 1.5 and 2.1 for patients with high periodon-
tal index scores or tooth loss at baseline to develop diabetes [10], while the second one found
no association between periodontal disease and the incidence of diabetes [11].
Gingival crevicular fluid (GCF) is a serum transudate found in the gingival sulcus. It contains
not only connective tissue degradation products but also inflammatory molecules derived from
circulating blood [12]. The levels of biomarkers in the GCF are potentially important as predic-
tors of disease progression [7]. Few studies have investigated the levels of diabetes-related bio-
markers in GCF such as ghrelin [13], leptin [14], and visfatin [15]. In the present study, the
multiplex biometric immunoassay technique was applied in order to determine the amounts of
10 diabetes-related protein biomarkers known to be involved in the regulation of glucose metab-
olism, namely: C-peptide, ghrelin, gastric inhibitory polypeptide (GIP), glucagon-like peptide-1
(GLP-1), glucagon, insulin, leptin, plasminogen activator inhibitor-1 (PAI-1), resistin and visfatin.
The aim of the study was to investigate the influence of chronic periodontitis on the levels
of glucoregulatory biomarkers in the GCF, by comparing the levels of the above biomarkers in
subjects with T2DM, with and without chronic periodontitis, and in subjects without diabetes,
with and without chronic periodontitis. We tested the hypothesis that in patients with T2DM,
chronic periodontitis interferes with the regulation of glucose metabolism and that this effect
is reflected in the relative quantities of the corresponding glucoregulatory biomarkers in the
GCF, compared to the levels in subjects with T2DM who do not have chronic periodontitis.
The second hypothesis tested was that in subjects without T2DM, chronic periodontitis is as-
sociated with increased GCF levels of biomarkers known for their association with the onset
of T2DM.
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Materials and Methods
Subjects and study design
The sample population comprised a total of 152 participants, 78 with T2DM and 74 without
T2DM, representing a randomly selected subset from 461 participants recruited for a previous
study by Mohamed et al. [16]. The T2DM subjects were stratified according to periodontal sta-
tus, into two groups: 54 with chronic periodontitis (G1) and 24 without periodontitis (G2).
Subjects without T2DM were also stratified according to periodontal status, into two groups:
30 with chronic periodontitis (G3) and 44 without periodontitis (G4). The T2DM subjects
were recruited from The Jaber Abol’ez Diabetes Center in Khartoum-Sudan. T2DM was diag-
nosed by specialist physicians at the center according to the criteria of The American Diabetes
Association [17]. Briefly, diagnosis of T2DM was based on one of the following: fasting plasma
glucose of 126 mg/dl ( 7.0 mmol/L), random plasma glucose of 200 mg/dl ( 11.1
mmol/L), or plasma glucose of 200 mg/dl ( 11.1 mmol/L) after 75 g oral glucose tolerance
test. A glycated haemoglobin test (HbA1c) was undertaken at the center’s laboratory, using a
commercially available kit (LabonaCheck A1c analyzer). Subjects without T2DM were re-
cruited from the out-patient dental clinic at the Khartoum Dental Teaching Hospital. Recruit-
ment of the study participants and the eligibility criteria for enrolment have been described in
detail elsewhere [16]. Briefly, the criteria for enrolment were (i), being diagnosed with T2DM
for more than one year and attending a specialized diabetes clinic-for the T2DM patients- (ii),
having at least for 10 remaining teeth (iii), no antibiotic, no steroidal and/or non-steroidal
anti-inflammatory medication used during the last 3 weeks (iv), not treated with immunosup-
pressive chemotherapy, no current acute illness, no professional periodontal treatment received
during the last 6 months and no ongoing pregnancy or lactation.
The study protocol was approved by the Ministry of Health in the Sudan and by the Norwe-
gian Research Ethics Committee at the University of Bergen (2012/1470/REK Vest). Participa-
tion was confirmed by written informed consent and the steps of the clinical examination and
sampling procedures were explained to each participant. All participants were provided with
oral and written oral hygiene instructions, informed of their dental diagnosis and referred for
appropriate dental treatment if needed.
Clinical examination
Periodontal examination included all teeth except 3rd molars. All participants were examined
by a single, calibrated examiner (HGM) using a color-coded periodontal probe (N22, 2-4-6-8-
10-12 mmmarkings), a color-coded Nabors furcation probe (NAB2, 3-6-9-12 mmmarkings),
curette, mirror, probe, tweezers and cotton rolls. Dental plaque was recorded according to the
Silness and Loe Index [18]. Periodontal pocket depths (PD) were measured from the gingival
margin to the base of the periodontal pocket (mm) at four sites on each tooth (mesial, distal,
buccal and lingual). Subjects with at least two sites with PD of 4 mm (not on the same tooth)
with bleeding on probing were diagnosed as having chronic periodontitis [19,20]. It was re-
ported that both periodontal pocket depth and bleeding on probing reflect the current disease
status and are strongly related to the local inflammatory activity [21,22].
GCF sampling
Before the clinical examination, GCF samples were collected on the same day, using paper
strips (PERIOPAPER Gingival Fluid Collection Strips, Oraflow Inc, New York, USA). Four
samples, representing the four quadrants, were collected from each participant. Samples were
collected from the mesiobuccal site of the sulcus/pocket. The 1st molar or, if missing, the 2nd
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molar, 2nd premolar or 1st premolar was sampled respectively. If the target teeth were missing
in one quadrant, then no GCF sample was collected from that quadrant. After removing the
supra-gingival biofilm with sterile cotton pellets, the sites were dried and isolated with cotton
rolls to avoid saliva contamination. To collect the GCF, the paper strips were inserted 2 mm
into the sulcus/pocket and left in place for 30 seconds. Strips that were visually assessed as con-
taminated with blood or saliva were discarded. The four strips were immediately pooled in one
tube, labeled and stored in liquid nitrogen until analysed.
Protein extraction and quantification
For protein extraction, Tween buffer was added to each GCF sample (4 strips). The tubes were
kept in a shaker for 30 minutes and then centrifuged for 10 minutes at 4°C and 1400 rpm. The
extracted protein was quantified using a commercially available kit (Pierce BCA Protein Assay
Kit, Thermoscientific, Rockford, USA) following the manufacturer’s instructions. Absorbance
was measured at 560 nm on a plate reader (FLUOstar OPTIMA- BMG Labtech, Germany) and
the total protein per sample (4 strips) was calculated in micrograms (μg).
Multiplex biomarkers assay
Multiplex biometric immunoassay containing fluorescent dyed magnetic beads conjugated
with monoclonal antibodies specific for the targeted 10 protein biomarkers was used according
to the manufacturer's instructions (Bio-Plex Human Cytokine Assay; Bio-Rad Inc., Hercules,
CA, USA) [23]. Following protein extraction and purification, GCF samples were diluted to a
ratio of 1:4 and incubated with the magnetic beads. After a series of washes with Bio-Plex Pro
wash station, biotinylated detection antibody was added to create a sandwich complex. There-
after, Streptavidin-Phycoerythrin conjugate was added as a fluorescent indicator. A range of
(352290–0.97) pg/ml recombinant cytokines was used to establish the standard curves. Bio-
markers quantities were determined using a multiplex array reader powered by Luminex-200
System. The amounts were calculated using Bio-Plex Manager software and reported as pico-
grams per 30 seconds (pg/30 s) [24].
Statistical analysis
Comparisons were made between the T2DM groups (G1 and G2) and between the groups
without T2DM (G3 and G4) independently. Distributions of the continuous variables among
each group were assessed using Kolmogorov-Smirnov test. Independent sample-T test, Mann-
Whitney U test, chi-square test and Fisher’s Exact test were used to investigate the differences
in the distribution of demographic data between the study groups. Quantities of the detected
biomarkers were compared between the study groups using Mann-Whitney U test. Logistic re-
gression analysis adjusting for age, gender, dental plaque and total protein was applied to test
the relationship between periodontal status and the quantities of biomarkers. Spearman’s cor-
relation coefficients were calculated to assess the correlation between the number of sites with
PD 4 mm and the amount of each biomarker. Stata 13 (Stata Corp. 2013, Stata Statistical
Software: Release 13. College Station, TX: StataCorp LP) was used for statistical analysis. P val-
ues less than 0.05 were considered statistically significant.
Results
As presented in Table 1, the mean ages of the T2DM patients in G1 and G2 were 54.76 ± 1.38
and 50.79 ± 2.09 (P>0.05), respectively. The age ranges were 24–70 and 33–70 years, respec-
tively. There were no significant intergroup differences between G1 and G2 in the demographic
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and clinical indicators. Oral hypoglycemic drugs were the most common drugs for treatment
of diabetes in G1 (66.7%) and insulin in G2 (50.0%). In subjects without T2DM, the mean ages
of G3 and G4 were 55.37 ± 1.77 and 47.15 ± 1.56 (P<0.01), respectively. The age ranges were
38–70 and 24–65 years, respectively. Plaque index was the only clinical indicator that differed
significantly between G3 and G4. Among those with chronic periodontitis, the PD ranged
from 4 to 10 mm in G1, and from 4 to 6 mm in G3, while participants without chronic peri-
odontitis (G2 and G4) had a normal gingival sulcus ranged from 1–3 mm.
Table 1. Demographic characteristics and clinical indicators of the study groups.
Type 2 diabetes No diabetes
Variable Chronic periodontitis
(G1), n = 54
No periodontitis (G2),
n = 24
P
value
Chronic periodontitis
(G3), n = 30
No periodontitis (G4),
n = 44
P
value
Age, mean (SE) 54.76 (1.38) 50.79 (2.09) 0.12a 55.37 (1.77) 47.15 (1.56) <0.01a
Gender, % (n) ) )
Male 42.60 (23) 29.20 (7) 0.38b 60.00 (18) 34.10 (15) 0.05b
Female 57.40 (31) 70.80 (14) 40.00 (12) 65.90 (29)
Education, % (n)
Literate 70.37 (38) 79.17(19) 0.42b 66.67 (20) 77.27 (34) 0.31b
Illiterate 29.63 (16) 20.83 (5) 33.33 (10) 22.73 (10)
Employment, % (n)
) )
Employed 37.04 (20) 29.17 (7) 0.50b 56.67 (17) 36.36 (16) 0.09b
Unemployed 62.96 (34) 70.83 (17) 43.33 (13) 63.64 (28)
Smoking, % (n) )
Yes 13.00 (7) 12.50 (3) 1.00c 26.70 (8) 13.60 (6) 0.27b
No 87.00 (47) 87.50 (21) 73.30 (22) 86.40 (38)
Plaque index, mean
(SE)
1.66 (0.05) 1.49 (0.05) 0.05a 1.49 (0.06) 1.28 (0.06) 0.03a
Pocket depth, % (n)
4–5 mm 59.30 (32) 0.00 (0) ——- 70.00 (21) 0.00 (0) ——-
 6 mm 40.70 (22) 0.00 (0) 30.00 (9) 0.00 (0)
Total protein -μg,
mean (SE)
82.78 (7.53) 77.53 (9.06) 0.92d 84.23 (15.25) 86.50 (9.51) 0.25d
Duration of T2DM,
mean (SE)
8.44 (0.83) 9.67 (1.70) 0.61d ——- ——- ——-
T2DM medication
used, % (n)
) ——- ——- ——-
Dilatory control 0.00 (0) 12.50 (3) <0.01c
Oral-hypoglycemic 66.70 (36) 33.30 (8)
Insulin 29.60 (16) 50.00 (12)
Both 3.70 (2) 4.20 (1)
HbA1c %, mean (SE) 9.17 (0.24) 9.25 (0.49) 0.89a ——- ——- ——-
a Independent sample-T test.
b Chi-square test.
c Fisher’s Exact test.
d Mann-Whitney U test.
n: sample size, SE: standard error of the mean, T2DM: type 2 diabetes, HbA1c: glycated haemoglobin.
doi:10.1371/journal.pone.0127660.t001
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Of the 10 glucoregulatory biomarkers investigated in this study, resistin was excluded from
the analysis, as it was not detected in 60% of the GCF samples. The mean quantities of the de-
tected diabetes-related biomarkers among the study groups are presented in Table 2.
After adjustment for potential confounders, GIP, GLP-1 and glucagon were significantly
higher in G1 than in G2. Moreover, C-peptide, insulin, ghrelin, leptin and PAI-1 were insignif-
icantly higher in G1 than in G2 (Table 3). In contrast, in subjects without T2DM, the levels of
C-peptide and ghrelin were significantly higher in G4 than in G3. All the other biomarkers
under investigation were insignificantly higher in G4 than in G3, except visfatin which was in-
significantly higher in G3 (Table 3).
As the number of diseased sites increased (PD 4 mm), the amount of C-peptide decreased
significantly (Spearman’s correlation co-efficient: -0.240). In contrast, the amounts of both GIP
Table 2. Amounts of the detected glucoregulatory biomarkers (pg/30 s).
Type 2 diabetes No diabetes
Biomarker, mean
(SE)
Chronic periodontitis
(G1),
No periodontitis
(G2),
P
valuea
Chronic periodontitis
(G3),
No periodontitis
(G4),
P
valuea
n = 54 n = 24 n = 30 n = 44
C-peptide 26.22 (0.87) 25.27 (1.55) 0.82 35.15 (1.91) 42.98 (2.52) 0.10
Insulin 24.36 (1.38) 20.02 (1.94) 0.12 25.59 (1.51) 30.92 (2.28) 0.17
GIP 164.21 (3.35) 144.64 (4.54) <0.01 141.45 (3.76) 151.27 (3.14) 0.07
GLP-1 210.99 (5.27) 183.40 (7.65) <0.01 188.63 (7.42) 203.02 (6.52) 0.30
Glucagon 261.77 (8.06) 223.82 (10.72) 0.01 242.91 (9.40) 250.17 (7.29) 0.60
Ghrelin 303.63 (15.82) 239.00 (19.34) 0.04 303.20 (19.00) 374.22 (21.91) 0.03
Leptin 85.85 (5.52) 64.78 (5.49) 0.05 84.46 (6.36) 99.57 (6.66) 0.14
PAI-1 1027.19 (155.80) 901.53 (260.49) 0.32 512.54 (86.75) 619.04 (110.98) 0.18
Visfatin 6411.37 (471.25) 5976.73 (1201.05) 0.13 7013.91 (978.87) 5194.03 (414.78) 0.26
a Mann-Whitney U test.
n: sample size, SE: standard error of the mean, GIP: gastric inhibitory polypeptide, GLP-1: glucagon-like peptide-1, PAI-1: plasminogen activator inhibitor-1.
doi:10.1371/journal.pone.0127660.t002
Table 3. Logistic regression analysis with periodontal status as dependent variable (yes/no).
Type 2 diabetes No diabetes
Biomarker Coefﬁcient (SE) OR (95% CI) P valuea Coefﬁcient (SE) OR (95% CI) P valuea
C-peptide 0.008 (0.041) 1.008 (0.931–1.092) 0.85 -0.053 (0.023) 0.948 (0.907–0.992) 0.02
Insulin 0.060 (0.033) 1.062 (0.996–1.133) 0.07 -0.049 (0.027) 0.952 (0.902–1.005) 0.07
GIP 0.035 (0.014) 1.035 (1.008–1.064) 0.01 -0.028 (0.016) 0.972 (0.942–1.003) 0.08
GLP-1 0.022 (0.010) 1.022 (1.003–1.042) 0.02 -0.009 (0.007) 0.991 (0.977–1.006) 0.12
Glucagon 0.013 (0.006) 1.013 (1.001–1.025) 0.03 -0.003 (0.006) 0.997 (0.986–1.008) 0.60
Ghrelin 0.005 (0.003) 1.005 (0.999–1.010) 0.11 -0.006 (0.003) 0.994 (0.989–0.999) 0.02
Leptin 0.016 (0.010) 1.016 (0.997–1.036) 0.09 -0.015 (0.008) 0.985 (0.970–1.001) 0.06
PAI-1 0.006 (0.024) 1.006 (0.959–1.054) 0.82 -0.079 (0.058) 0.924 (0.825–1.035) 0.17
Visfatin -0.001 (0.006) 0.999 (0.986–1.011) 0.85 0.009 (0.008) 1.009 (0.993–1.025) 0.27
a Adjusted for age, gender, plaque index and total GCF protein.
OR: adjusted odds ratio, CI: conﬁdence interval, SE: standard error, GIP: gastric inhibitory polypeptide, GLP-1: glucagon-like peptide-1, PAI-1:
plasminogen activator inhibitor-1.
doi:10.1371/journal.pone.0127660.t003
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and visfatin increased significantly as the number of diseased sites increased (Spearman’s cor-
relation co-efficient: 0.255 and 0.241, respectively). We also observed a weakly positive correla-
tion between the number of sites with PD 4 mm and the amounts of both GLP-1 and
glucagon (Spearman’s correlation co-efficient: 0.131 and 0.153, respectively) (Table 4).
Discussion
There is ample evidence from the scientific literature that the relationship between diabetes
and chronic periodontitis is bidirectional [25,26]. However, the focus of this report was to in-
vestigate the impact of chronic periodontitis on levels of glucoregulatory biomarkers in the
GCF. In the present study, chronic periodontitis adversely influenced the levels of glucoregula-
tory biomarkers in the GCF, indicating that it might be associated with the onset of T2DM and
the risk of diabetes related medical complications in subjects with the disease. Multiplex tech-
nology has been applied in a few studies, to investigate diabetes-related biomarkers in patients
with systemic conditions such as obesity [27] and gestational diabetes [28]. In the present
study, this high-throughput technology provided a highly accurate analysis of biological sam-
ples, given that it requires less sample volume and is able to detect different proteins within a
broad range of concentrations [29]. When tested on the same analytics, multiplex assays are re-
ported to compare favorably with ELISA with respect to sensitivity, accuracy, and reproducibil-
ity [30].
C-peptide is a polypeptide secreted from the secretory granules of β-cells during the conver-
sion of pro-insulin to insulin [31]. C-peptide and insulin are released into the circulation in
comparable amounts, but C-peptide is a more reliable indicator of β-cell activity, as it has a lon-
ger half-life and is not affected by insulin-specific antibodies [32]. To date, there are no pub-
lished data on the relationship between periodontal disease and C-peptide levels in adults with
T2DM. However, Merchant et al., [33] investigated such an association in a sample comprising
young subjects with both type 1 and 2 diabetes and concluded that periodontal disease was as-
sociated with lower fasting C-peptide. We observed the same trend among subjects without
T2DM, as the level of C-peptide was lower among subjects with periodontitis (G3) than in
those without periodontitis (G4). Moreover, the amount of C-peptide was negatively correlated
with the number of diseased sites with PD 4 mm, suggesting that chronic periodontitis
might be associated with disturbed β-cells activity. In the present study, comparisons of insulin
Table 4. Correlations between number of sites with PD 4mm and the amounts of the detected
biomarkers.
Biomarker Correlation coefﬁcienta P value
C-peptide -0.240 <0.01
Insulin -0.005 0.95
GIP 0.255 <0.01
GLP-1 0.131 0.11
Glucagon 0.153 0.06
Ghrelin -0.017 0.84
Leptin 0.030 0.72
PAI-1 0.081 0.32
Visfatin 0.241 <0.01
a Spearman’s correlation.
GIP: gastric inhibitory polypeptide, GLP-1: glucagon-like peptide-1, PAI-1: plasminogen activator inhibitor-
1.
doi:10.1371/journal.pone.0127660.t004
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among the different study groups showed similar trends, but there was no correlation between
insulin and the severity of periodontal disease.
GLP-1 and GIP are insulin-stimulating hormones secreted from the gastrointestinal system
after food intake [34]. Patients with T2DM do not generally exhibit reduced GLP-1 secretion
[35]. In contrast, results from studies comparing GIP levels in T2DM patients and systemically
healthy controls were inconclusive [34]. In the present study, both GIP and GLP-1 were found
to be significantly higher in G1 than in G2. This observation may be attributable to the fact
that 50% of patients in G2 were under insulin therapy, compared to 29.6% in G1. Thus, exoge-
nous insulin might have down-regulated the insulin-stimulating hormones by negative feed-
back. Moreover, the levels of GIP and GLP-1 were lower in G3 than in G4. Despite the statisti-
cal insignificance, these findings support the hypothesis that chronic periodontitis is associated
with disturbed GCF levels of hormones responsible for regulating the blood glucose levels
among individuals without T2DM.
Glucagon is a hormone secreted by α-cells in response to food intake and hypoglycemia
[36]. It regulates blood glucose levels and counteracts the effect of insulin by increasing blood
glucose levels. In T2DM, the feed-back mechanism which controls glucagon secretion in re-
sponse to blood glucose level seems to malfunction [37]. Thus, glucagon remains inappropri-
ately elevated in hyperglycemia at comparable levels of blood glucose. Our results indicated
no statistical difference in glucagon between G3 and G4. In subjects with T2DM however, the
amount of glucagon was higher in G1 than in G2. This finding suggests that in T2DM sub-
jects, chronic periodontitis may exert a systemic effect by its association with increased
glucagon secretion.
Ghrelin is a peptide hormone secreted from the oral epithelium and fibroblasts. It has a
major role in regulating neutrophil-mediated innate immune response [13]. Low ghrelin con-
centration is associated with T2DM [38]. The amount of ghrelin in G3 was significantly lower
than in G4. Yilmaz et al., [39] reported inconclusive results in a study investigating the level of
plasma ghrelin in systemically healthy subjects with and without periodontitis. In the present
study, the opposite trend was observed in the T2DM groups, as those with chronic periodonti-
tis had higher levels of ghrelin than those without periodontitis. One explanation is that there
might be a synergistic systemic effect of both T2DM and chronic periodontitis, as high ghrelin
levels have been reported in other chronic inflammatory diseases such as Crohn’s disease and
inflammatory bowel disease [40].
Leptin is a hormone secreted by adipose tissues. It exerts an anti-diabetic effect by reducing
insulin resistance [41]. The leptin detected in GCF probably diffuses from the microvasculature
to the gingival tissues, as there are no adipocytes within the gingival tissue [14]. Tatti et al., [42]
have reported higher leptin concentration in systemically healthy individuals than in those with
T2DM. In contrast, earlier investigations comparing Sudanese adults with and without diabetes
have reported elevated plasma leptin levels in subjects with diabetes [43]. The present findings
with respect to subjects without T2DM are consistent with earlier reports of higher levels of lep-
tin in periodontally healthy subjects than in those with periodontal disease [14,44]. This has
been attributed to the fact that during inflammation, the amount of leptin decreases because the
increased vascular permeability allows leptin to escape from the gingival tissue [44]. In this con-
text, it is noteworthy that detection of high local leptin levels in T2DM patients with periodontal
disease is regarded as one of the indicators of cardiovascular complications [45]. PAI-1 is a ser-
ine protease inhibitor secreted by endothelial cells, fibroblasts, liver and adipose tissue [46]. In-
creased PAI-1 concentration is reported to be associated with venous thrombosis, pulmonary
embolism and the aetiology of T2DM [47,48]. In the present study, the results of PAI-1 were in-
significant. Visfatin is an adipokine secreted mainly by visceral adipose tissue [49]. It is also se-
creted by neutrophils in response to pathogens and acts as a pro-inflammatory cytokine which
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stimulates monocytes to produce inflammatory mediators [50]. In the present study, there was
a significant positive correlation between PD and visfatin, a finding which is in concordance
with a previous report by Pradeep et al [15].
It was not possible to measure the GCF volume. Instead, we used total GCF protein as a sur-
rogate measure of the GCF volume in the multivariate analysis as an attempt to control for the
potential effect of variability of GCF volume on our results [51]. Data on the study participant’s
height and weight were unavailable. Thus, we were not able to calculate the body mass index
(BMI) which is a proxy variable reflecting the amount of adipose tissue for each participant.
This might affect our findings, as some of the biomarkers studied are secreted by adipocytes
such as leptin, PAI-1 and visfatin.
Within the limitations of the study, our data imply that chronic periodontitis is associated
with disturbance of the local expressions of biomarkers related to the onset of T2DM and its
medical complications in GCF. Large-scale longitudinal studies are required to confirm the as-
sociation between chronic periodontitis and the onset of T2DM and its medical complications.
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